The past FY25/1Q26 results confirmed sequential improvement in the fundamentals of China's healthcare sector, propelled by innovative drugs and CDMOs, Citi said in a report. Domestic medical technology, healthcare services and pharmacy segments have bottomed out. Innovation is beginning to generate returns. Sales of innovative drugs are accelerating, while CXO order volumes have notched a record high.Citi updated its Hong Kong Buy list, which includes HENGRUI PHARMA (01276.HK) -0.650 (-0.979%) Short selling $66.91M; Ratio 27.140% , CSPC PHARMA (01093.HK) -0.180 (-2.261%) Short selling $110.25M; Ratio 18.760% , ASCLETIS-B (01672.HK) -0.540 (-3.125%) Short selling $4.81M; Ratio 10.213% , INNOVENT BIO (01801.HK) -4.700 (-5.421%) Short selling $464.13M; Ratio 24.743% , WUXI APPTEC (02359.HK) -2.200 (-1.691%) Short selling $408.50M; Ratio 38.774% , WUXI BIO (02269.HK) +1.040 (+3.186%) Short selling $141.29M; Ratio 11.876% , ALI HEALTH (00241.HK) -0.300 (-6.608%) Short selling $660.71M; Ratio 40.092% , MEDBOT-B (02252.HK) -0.500 (-1.905%) Short selling $7.97M; Ratio 8.072% , MINDRAY BIO-MEDICAL (300760.SZ) -0.870 (-0.540%) , AIER EYE (300015.SZ) -0.200 (-1.855%) and YIFENG PHARMACY (603939.SH) -0.610 (-2.580%) . Its Top Sells include CR MEDICAL (01515.HK) -0.030 (-1.083%) Short selling $407.88K; Ratio 7.303% and BLOOMAGE BIOTECH (688363.SH) -0.560 (-1.383%) . (HK stocks quote is delayed for at least 15 mins.Short Selling Data as at 2026-05-15 16:25.) (A Shares quote is delayed for at least 15 mins.)Related News Citi: ALI HEALTH (00241.HK) FY Results Largely In Line; First-Ever Dividend Shows Confidence
AASTOCKS Financial News